शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ALBERTDAVDBSEAlbert David Ltd-$· Pharmaceuticals & BiotechnologyCriticalNegative
Announced Fri, 19 Dec, 2025 · 16:24 IST

Resignation of Mr. Umesh Manohar Kunte, Managing Director w.e.f. 18-12-2025.

CEO resignedKey managerial personnel resignedManagement Changes View source PDFExplain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.1%Reaction day
₹743.10
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-0.3% vs market
Pharmaceuticals peers, median of 155sector+0.7%+0.4% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.1+1.4-0.3+0.7+0.4
Next day
+0.9+1.4-0.5+0.6+0.3
2d
+0.9+0.9+0.1+0.6+0.3
3d
+1.1+0.3+0.7+0.0+1.0
4d
-0.4-0.4+0.0-0.7+0.3
5d
-0.8-0.5-0.3-0.8+0.0
1w
-0.0+1.1-1.1+0.1-0.1
15d
-1.5-2.5+1.0-2.1+0.6
1m
-7.8-6.1-1.7-5.9-1.9
2m
-3.2-2.8-0.4-5.6+2.4
3m
-14.0-14.9+0.9-13.4-0.6
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Umesh Manohar Kunte has resigned from the Board of Albert David Ltd as Managing Director, CEO, and Director, effective from the close of business hours on December 18, 2025. The resignation is cited as being due to personal reasons and priorities, with a three-month notice period mentioned. He will also cease to be a Key Managerial Person under the Companies Act, 2013. The Board accepted the resignation at its meeting held on the same day and recorded appreciation for his services. No successor or replacement has been announced in this filing.

Likely market impact

The sudden exit of the MD & CEO, a top leadership role, may create short-term uncertainty around strategic continuity and could be viewed negatively by the market until a successor is named. Shareholders should watch for a follow-up announcement regarding the appointment of a new MD/CEO.